PAREXEL Simplifies Drug Development Journey From Science To New Treatments


Company News Release

"Your Journey. Our Mission." communicates company's new brand promise

As the global biopharmaceutical industry increasingly seeks to streamline the complex process of bringing new drugs to market, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of a new marketing initiative that highlights the Company's proven approach to help clients simplify the journey from science to new treatments.

Drug development today is a demanding and difficult process. Increasingly, pharmaceutical companies are under pressure to accelerate development and introduce innovative new medicines and treatments in an increasingly complex and competitive environment. To assist in these efforts, companies are seeking a partner that can help simplify and accelerate all aspects of product development.

"In today's market, biopharmaceutical companies must effectively balance global requirements with regional and local issues, address clinical trial complexity and seek ways to make the drug development process more efficient," said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International. "For more than 30 years, our mission has been to help the biopharmaceutical and medical device industries prevent and cure disease. While that mission hasn't changed, the way we promote our mission is changing. PAREXEL's new brand platform clearly defines how we can simplify drug development by applying our unique capabilities to the work we do. This will help clients better understand the full scope of our portfolio, and how individual offerings interrelate."

Your Journey. Our Mission.™

PAREXEL's new brand promise, "Your Journey. Our Mission™ ," represents the Company's commitment to make each client's journey its mission. The Company works to fulfill this commitment through its:

  • Global Expertise: Today, it is not enough to have a large global footprint. PAREXEL's drug development experts are connected through common processes, standards and technology, so regardless of where a study is conducted, the same standards of quality apply. With 76 locations in 50 countries, PAREXEL cooperates and collaborates globally to provide services and share best practices around the world. PAREXEL brings value to clients throughout the entire product life cycle by putting to work its deep understanding of science, technology, regulatory and business issues combined with global resources and local knowledge of region-specific requirements.

  • Drive to Solve the Complex: From its fully integrated Perceptive MyTrials®eClinical technology platform to its pioneering regulatory work in biosimilars, PAREXEL is constantly working to solve complex challenges for clients by optimizing integrated offerings in new and innovative ways.

  • Recognition of the Bigger Journey:  PAREXEL led the development of Strategic Partnerships in the biopharmaceutical industry, enabling companies to optimize the entire drug development process. These close, long-term partnerships drive deeper collaboration, speed up development cycles and reduce cost, according to PAREXEL's Strategic Partnerships 2013 report. It revealed that 85 percent of the biopharmaceutical executives surveyed believe Strategic Partnerships have positively impacted CRO-sponsorship relationships.

As part of its global marketing and advertising campaign, PAREXEL has also launched a new corporate website that provides an enhanced visitor experience, more clearly distinguishes PAREXEL's products and services, and communicates the Company's true value to clients.  The website features several videos that illustrate the company's global expertise as well as its ability to manage complexity and develop meaningful Strategic Partnerships

"We believe the world will be a healthier place when the journey between science and new treatments becomes simpler," saidChristopher Tama, Worldwide Head of Marketing, PAREXEL. "This belief is the foundation of our story, which we are now beginning to tell in new and creative ways."   

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.